Background: Since the first report of clonidine, an α2-adrenoceptor agonist, the indications for this class of drugs have continued to expand. In December 1999, dexmedetomidine was approved as the most recent agent in this group and was introduced into clinical practice as a short-term sedative (<24 hours) Aims & Objectives: To study the effect of dexmedetomidine on sedation, hemodynamic values, anesthetic consumption, and recovery from anesthesia. Methodology: The study includes Forty-two female patients undergoing gynaecologic surgery were randomly assigned to receive IV Dex (1µg/kg: Dex group) or saline (control group) over 10 min before anaesthetic induction. After tracheal intubation, anaesthesia was maintained with sevoflurane, o2 (50%) N2o (50%). Results: Mean arterial pressure (MAP) and heart rate (HR) after intubation were increased in Control group, but did not change in the Dex group. The HR of the Dex group was lower compared to that of the Control group during maintenance; no difference in MAP between the groups. End-tidal concentration and total cumulative consumption of sevoflurane were lower in the Dex group than in the control group. Recovery profiles, postoperative nausea, voming, and visual analogue pain score were not significantly different between the groups Conclusion: single infusion of Dex(1 µg/kg) is a simple, easy and economical adjuvant for general anesthesia. Dex maintains stable hemodynamics and decreases anestbetic consumption without changing recovery profiles.